Back to Journals » Cancer Management and Research » Volume 12

Emerging Roles of Long Noncoding RNA Regulator of Reprogramming in Cancer Treatment

Authors Sun DE, Ye SY

Received 9 March 2020

Accepted for publication 9 June 2020

Published 21 July 2020 Volume 2020:12 Pages 6103—6112


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Ahmet Emre Eskazan

Di-Er Sun,1,2 Shu-Yuan Ye1,2

1Clinical Laboratory, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, People’s Republic of China; 2Clinical Laboratory, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, Zhejiang, People’s Republic of China

Correspondence: Shu-Yuan Ye
Clinical Laboratory, Ningbo HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, People’s Republic of China

Abstract: Despite numerous advances in cancer treatment, the global prevalence and cancer-related mortality remain high. Understanding tumor initiation and progression mechanisms are critical as it will lead to the development of interventions for improving the prognosis of cancer patients. The roles of long noncoding RNAs (lncRNAs) in cancer have attracted immense research interest. Growing evidence indicates that lncRNA regulator of reprogramming (linc-ROR), a well-studied RNA, regulates the progression of various cancers, such as lung cancer (LC), hepatocellular carcinoma (HCC), breast cancer (BC), colorectal cancer (CRC), pancreatic cancer (PC), papillary thyroid carcinoma (PTC), or esophageal squamous cell carcinoma (ESCC). linc-ROR promotes the proliferation, invasion, migration and chemoresistance of cancer cells. Herein, we reviewed current literature on the modulatory functions and mechanisms of linc-ROR in cancer development. We highlight new linc-ROR-related therapeutic strategies in cancer treatment.

Keywords: cancer, long noncoding RNA, linc-ROR, mechanisms, clinical application

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]